OraSure Technologies, Inc. (OSUR) Position Maintained by Rational Advisors LLC
Rational Advisors LLC continued to hold its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,200 shares of the medical instruments supplier’s stock at the end of the second quarter. Rational Advisors LLC’s holdings in OraSure Technologies were worth $107,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the stock. Norges Bank acquired a new position in OraSure Technologies during the fourth quarter worth about $9,786,000. Louisiana State Employees Retirement System acquired a new position in OraSure Technologies during the first quarter worth about $287,000. Nationwide Fund Advisors increased its position in OraSure Technologies by 209.1% in the first quarter. Nationwide Fund Advisors now owns 144,922 shares of the medical instruments supplier’s stock worth $1,874,000 after buying an additional 98,034 shares during the last quarter. Fisher Asset Management LLC increased its position in OraSure Technologies by 48.6% in the first quarter. Fisher Asset Management LLC now owns 503,594 shares of the medical instruments supplier’s stock worth $6,511,000 after buying an additional 164,630 shares during the last quarter. Finally, Profund Advisors LLC acquired a new position in OraSure Technologies during the first quarter worth about $137,000. 89.76% of the stock is currently owned by hedge funds and other institutional investors.
OraSure Technologies, Inc. (OSUR) opened at 20.53 on Wednesday. The stock has a market cap of $1.22 billion, a P/E ratio of 37.95 and a beta of 1.57. The firm’s 50-day moving average is $18.76 and its 200 day moving average is $14.33. OraSure Technologies, Inc. has a one year low of $6.84 and a one year high of $21.59.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The business had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. During the same quarter in the prior year, the firm posted $0.07 EPS. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, analysts anticipate that OraSure Technologies, Inc. will post $0.48 EPS for the current fiscal year.
A number of equities analysts recently issued reports on OSUR shares. Jefferies Group LLC raised their price objective on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. Canaccord Genuity raised their price objective on shares of OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Saturday, May 6th. BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Finally, Stephens reissued an “overweight” rating and issued a $19.00 price objective (up previously from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $15.46.
In other OraSure Technologies news, Director Ronny B. Lancaster sold 89,684 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $14.79, for a total value of $1,326,426.36. Following the sale, the director now owns 6,295 shares in the company, valued at approximately $93,103.05. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Ronald H. Spair sold 510,112 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $20.66, for a total value of $10,538,913.92. Following the completion of the sale, the chief financial officer now owns 208,606 shares in the company, valued at approximately $4,309,799.96. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,036,670 shares of company stock worth $19,807,152. Insiders own 7.80% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.